The Gastrointestinal Safety of Orforglipron, a GLP-1 Receptor Agonist, in Adults With or Without Type 2 Diabetes: A Network Meta-Analysis of Randomized Controlled Trials - PubMed
2 hours ago
- #GLP-1 Receptor Agonist
- #Orforglipron
- #Gastrointestinal Safety
- Orforglipron (OFG) is an oral small-molecule GLP-1 receptor agonist with weight loss and glycemic benefits, but its gastrointestinal safety was evaluated via network meta-analysis.
- All OFG doses (3, 12, 24, 36, 45 mg) increased GI adverse events versus placebo, showing a dose-response trend, especially nausea, vomiting, diarrhea, and discontinuation due to GI events at high doses.
- No dose increased pancreatitis risk, but higher doses reduced ALT (e.g., 24 mg) and increased lipase and pancreatic amylase without clinical events, with effects consistent in patients with or without type 2 diabetes.